TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25154147

Group type: EXPERIMENTAL
Intervention: Two small incision technique
Number of subjects: 56

Group type: COMPARATOR
Intervention: Single long midline incision technique
Number of subjects: 56
Study: 21397316

Group type: EXPERIMENTAL
Intervention: Solobond M + Grandio
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Syntac + Tetric Ceram
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both materials
Number of subjects: 30
Study: 18707846

Group type: EXPERIMENTAL
Intervention: Infliximab (3mg/kg) at weeks 0, 2, 6 and 14
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Infliximab (3mg/kg) administered at baseline
Number of subjects: 20
Study: 16939405

Group type: EXPERIMENTAL
Intervention: Low-level whole body vibration (30 Hz, 0.3g) for 10 minutes daily for 12 months
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Low-level whole body vibration (30 Hz, 0.3g) for 10 minutes daily for 12 months (per protocol analysis)
Number of subjects: 48
Study: 14510790

Group type: EXPERIMENTAL
Intervention: Mild laser treatment using an argon green laser
Number of subjects: 38

Group type: COMPARATOR
Intervention: Observation (Control)
Number of subjects: 38
Study: 11376359

Group type: EXPERIMENTAL
Intervention: Brewer's yeast (23.3ug Cr/day)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: CrCl3 (200ug Cr/day)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study: 9108387

Group type: EXPERIMENTAL
Intervention: recombinant human IL-10 (rhIL-10; 25 microg/kg) pre-treatment
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: recombinant human IL-10 (rhIL-10; 25 microg/kg) post-treatment
Number of subjects: 16

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: recombinant human IL-10 (rhIL-10; 25 microg/kg) pre-treatment and post-treatment
Number of subjects: 16
Study: 8211871

Group type: EXPERIMENTAL
Intervention: Nebulised amiloride
Number of subjects: 24

Group type: COMPARATOR
Intervention: Nebulised saline (placebo)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Nasal potential difference measurement after amiloride
Number of subjects: 24

Group type: COMPARATOR
Intervention: Nasal potential difference measurement after saline
Number of subjects: 24
Study: 3530773

Group type: EXPERIMENTAL
Intervention: Flunarizine
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 29459150

Group type: EXPERIMENTAL
Intervention: Combination of 1 cartridge of 4% prilocaine plain plus 1 cartridge of 2% lidocaine with 1:100,000 epinephrine
Number of subjects: 118

Group type: COMPARATOR
Intervention: Combination of 2 cartridges of 2% lidocaine with 1:100,000 epinephrine
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Combination of 4% prilocaine plain plus 2% lidocaine with 1:100,000 epinephrine
Number of subjects: 118
Study: 27137970

Group type: EXPERIMENTAL
Intervention: Health Buddy (HB) - telehealth monitoring intervention
Number of subjects: 25

Group type: COMPARATOR
Intervention: Intensive Case Monitoring (ICM) alone
Number of subjects: 25
Study: 25204100

Group type: EXPERIMENTAL
Intervention: Women with ACoA syndrome
Number of subjects: 110

Group type: COMPARATOR
Intervention: Women without parental alcoholism in childhood (control group)
Number of subjects: 110
Study: 23131288

Group type: EXPERIMENTAL
Intervention: Ulinastatin (UTI) treatment, 200 kU every 8 hours
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (conventional treatment)
Number of subjects: 60
Study: 20367218

Group type: EXPERIMENTAL
Intervention: 40 g/day palatinose-blended sugar (PS group)
Number of subjects: 50

Group type: COMPARATOR
Intervention: 40 g/day sucrose (S group)
Number of subjects: 50
Study: 18501139

Group type: EXPERIMENTAL
Intervention: AM3
Number of subjects: 253
Study: 15983450

Group type: EXPERIMENTAL
Intervention: 30% inspired oxygen in air plus intravenous administration of saline
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: 80% inspired oxygen in air plus intravenous administration of saline
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: 30% inspired oxygen in air plus 75 microg/kg ondansetron intravenously
Number of subjects: 210
Study: 12667024

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 1715

Group type: EXPERIMENTAL
Intervention: Irbesartan
Number of subjects: 1715

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1715
Study: 10372238

Group type: EXPERIMENTAL
Intervention: 20 mg fenfluramine three times a day and 37.5 mg phentermine daily (n = 23)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Dual placebos (n = 21)
Number of subjects: 44
Study: 9092419

Group type: EXPERIMENTAL
Intervention: Aspirin (100-300 mg/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ticlopidine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aspirin (for primary prevention)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 0
Study: 1931470

Group type: EXPERIMENTAL
Intervention: Magnesium hydroxide (850 mg) with non-micronised glibenclamide (2.5 mg)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Magnesium hydroxide (850 mg) with micronised glibenclamide (1.75 mg)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Water only (150 ml) with micronised glibenclamide (1.75 mg)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Water only (150 ml) with non-micronised glibenclamide (2.5 mg)
Number of subjects: 13
Study: 6799077

Group type: EXPERIMENTAL
Intervention: Propranolol 40 mg four times a day
Number of subjects: 560

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 560

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 560
Study: 31860632

Group type: EXPERIMENTAL
Intervention: Topical benzydamine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Oral diclofenac
Number of subjects: 60

Group type: COMPARATOR
Intervention: Oral flurbiprofen
Number of subjects: 60
Study: 30373095

Group type: EXPERIMENTAL
Intervention: Delayed hard palate closure (DHPC) protocol
Number of subjects: 64

Group type: COMPARATOR
Intervention: Complete palatoplasty
Number of subjects: 64
Study: 27797992

Group type: EXPERIMENTAL
Intervention: Referral templates for 4 diagnostic groups (dyspepsia, suspected colorectal cancer, chest pain, chronic obstructive pulmonary disease) with intermittent surgery visits by study personnel.
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Referral templates intervention group
Number of subjects: 500

Group type: COMPARATOR
Intervention: Control group (standard referral practice)
Number of subjects: 500
Study: 25128052

Group type: COMPARATOR
Intervention: Hospital treatment as usual (7 days)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Early assisted discharge (3 days in hospital followed by treatment at home)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Attributes of early assisted discharge
Number of subjects: 0
Study: 22054782

Group type: EXPERIMENTAL
Intervention: Losartan/HCTZ combination therapy
Number of subjects: 91

Group type: COMPARATOR
Intervention: High-dose amlodipine monotherapy
Number of subjects: 91
Study: 18949456

Group type: EXPERIMENTAL
Intervention: Remifentanil-based regimen (n = 96) with propofol as required, for a maximum of 10 days.
Number of subjects: 205

Group type: COMPARATOR
Intervention: Conventional regimens (n = 109) of propofol, midazolam or lorazepam combined with fentanyl or morphine.
Number of subjects: 205
Study: 17125957

Group type: EXPERIMENTAL
Intervention: Patient-centered contraceptive counseling (n = 20)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Routine treatment (n = 21)
Number of subjects: 41
Study: 16372801

Group type: EXPERIMENTAL
Intervention: Hydrocortisone (cream)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Hydrocortisone (ointment)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Hydrocortisone butyrate (cream)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Hydrocortisone butyrate (ointment)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Mometasone furoate (cream)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Mometasone furoate (ointment)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Hydrocortisone butyrate
Number of subjects: 60
Study: 12126262

Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10868615

Group type: EXPERIMENTAL
Intervention: Single-dose miconazole nitrate (1200 mg) vaginal ovule
Number of subjects: 558

Group type: COMPARATOR
Intervention: Monistat 7 (miconazole nitrate 2%) Vaginal Cream
Number of subjects: 558
Study: 8800024

Group type: EXPERIMENTAL
Intervention: 20-slice, 3 mm slice thickness protocol
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: New 6 mm slice thickness protocol
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: 30-slice, 3 mm slice thickness protocol
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: 20-slice, 6 mm slice thickness protocol
Number of subjects: 324
Study: 1425900

Group type: EXPERIMENTAL
Intervention: Piroxicam suppository (20 mg)
Number of subjects: 24
Study: 4025494

Group type: EXPERIMENTAL
Intervention: Social activation program (experimental group)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 60
Study: 30986738

Group type: EXPERIMENTAL
Intervention: Brief cognitive behavioral therapy (n = 76)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Treatment as usual (n = 76)
Number of subjects: 152
Study: 30348185

Group type: EXPERIMENTAL
Intervention: GMCT (800 mg daily)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 27425566

Group type: EXPERIMENTAL
Intervention: Extended Class Exchange Program (ECEP)
Number of subjects: 322

Group type: COMPARATOR
Intervention: Control group (social‐emotional learning program)
Number of subjects: 322
Study: 24134922

Group type: EXPERIMENTAL
Intervention: Pay for Performance (P4P) intervention, introduced in 2004, with bonus payments for physicians meeting qualifying scores on Clinical Performance Vignettes (CPVs).
Number of subjects: 0
Study: 22840413

Group type: EXPERIMENTAL
Intervention: Transversus abdominis plane (TAP) block with 20 mL of 0.5% ropivacaine with epinephrine 1:200,000
Number of subjects: 58

Group type: COMPARATOR
Intervention: No TAP block (control group)
Number of subjects: 58
Study: 22453346

Group type: EXPERIMENTAL
Intervention: Interactive computer trainer
Number of subjects: 22

Group type: COMPARATOR
Intervention: Usual teaching
Number of subjects: 22
Study: 18230831

Group type: EXPERIMENTAL
Intervention: Methylprednisolone (MP) 500 mg administered intravenously over three consecutive days, in four cycles at 4 weekly intervals (total 6 g of MP).
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (PL) administered intravenously over three consecutive days, in four cycles at 4 weekly intervals.
Number of subjects: 15
Study: 15851425

Group type: EXPERIMENTAL
Intervention: Gaviscon Infant (625 mg in 225 ml milk)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (mannitol and Solvito N, 625 mg in 225 ml milk)
Number of subjects: 20
Study: 15320475

Group type: EXPERIMENTAL
Intervention: Endothelin receptor antagonists (selective ET-A and non-selective ET-A/B receptor antagonists)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Endothelin receptor antagonists
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Investigational drugs targeting endothelin system
Number of subjects: 0
Study: 10400482

Group type: EXPERIMENTAL
Intervention: 64 mg/day beta-carotene for 1 week
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 8712397

Group type: EXPERIMENTAL
Intervention: Low-flow sevoflurane anesthesia
Number of subjects: 100

Group type: COMPARATOR
Intervention: Isoflurane anesthesia
Number of subjects: 100
Study: 1810525

Group type: EXPERIMENTAL
Intervention: Meclofenamate sodium (100 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Piroxicam-beta-cyclodextrin (20 mg)
Number of subjects: 20
Study: 29884132

Group type: EXPERIMENTAL
Intervention: 111In-OTSA-101
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 90Y-OTSA-101 (Arm A: 370 MBq)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 90Y-OTSA-101 (Arm B: 1110 MBq)
Number of subjects: 20

Group type: COMPARATOR
Intervention: 90Y-OTSA-101
Number of subjects: 20
Study: 26908407

Group type: EXPERIMENTAL
Intervention: Pre-cardiopulmonary bypass arteries
Number of subjects: 12

Group type: COMPARATOR
Intervention: Post-cardiopulmonary bypass arteries
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Pre-cardiopulmonary bypass biopsies
Number of subjects: 12

Group type: COMPARATOR
Intervention: Post-cardiopulmonary bypass biopsies
Number of subjects: 12
Study: 24529697

Group type: EXPERIMENTAL
Intervention: Methylation triage (direct triage on self-sample by methylation analysis of MAL and miR-124-2 genes)
Number of subjects: 1024

Group type: COMPARATOR
Intervention: Cytology triage (triage by cytology on an additional physician-taken smear)
Number of subjects: 1024

Group type: EXPERIMENTAL
Intervention: Methylation triage
Number of subjects: 1024

Group type: COMPARATOR
Intervention: Cytology triage
Number of subjects: 1024
Study: 22709952

Group type: EXPERIMENTAL
Intervention: Seasonal inactivated trivalent influenza vaccine (TIV)
Number of subjects: 3697

Group type: COMPARATOR
Intervention: Control vaccine
Number of subjects: 3697
Study: 20647082

Group type: EXPERIMENTAL
Intervention: Operating microscope
Number of subjects: 96
Study: 18524542

Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Deflazacort
Number of subjects: 35
Study: 16014854

Group type: EXPERIMENTAL
Intervention: Trimethoprim/sulfamethoxazole (TRM/SMX)
Number of subjects: 45
Study: 12422922

Group type: EXPERIMENTAL
Intervention: Thyroidinum 30cH
Number of subjects: 208

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 208
Study: 10614792

Group type: EXPERIMENTAL
Intervention: rt-PA (recombinant tissue-type plasminogen activator)
Number of subjects: 45925

Group type: COMPARATOR
Intervention: PTCA (primary percutaneous transluminal coronary angioplasty)
Number of subjects: 45925
Study: 7862180

Group type: EXPERIMENTAL
Intervention: Botulinum toxin (80 units)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 1951002

Group type: EXPERIMENTAL
Intervention: Quinidine (600 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Mexiletine (400 mg)
Number of subjects: 20
Study: 7096998

Group type: EXPERIMENTAL
Intervention: Human diploid cell rabies vaccine, administered in 0.1 ml volumes intradermally (i.d.) or as 1.0 ml intramuscularly (i.m.)
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Three injections of human diploid cell rabies vaccine
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Booster doses administered by the subcutaneous (s.c.) or i.d. route
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Intradermal (i.d.) immunization
Number of subjects: 194
Study: 30417737

Group type: EXPERIMENTAL
Intervention: Open vein-graft harvesting
Number of subjects: 1150

Group type: COMPARATOR
Intervention: Endoscopic vein-graft harvesting
Number of subjects: 1150
Study: 29132250

Group type: EXPERIMENTAL
Intervention: Modified Pilates exercise program
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard physical education classes
Number of subjects: 80
Study: 27787269

Group type: EXPERIMENTAL
Intervention: ATX-101 2 mg/cm
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Topical and injectable lidocaine
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Ibuprofen and loratadine
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: ATX-101 treatment
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Injectable lidocaine with epinephrine
Number of subjects: 83
Study: 24928587

Group type: EXPERIMENTAL
Intervention: Acupuncture plus standard ED management
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard ED management alone
Number of subjects: 40
Study: 22003214

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.75% (25 mL) injected cephalad to the peroneal-tibial division (Group A)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Ropivacaine 0.75% (25 mL) injected caudad to the peroneal-tibial division (Group B)
Number of subjects: 102
Study: 19095838

Group type: EXPERIMENTAL
Intervention: ProSeal laryngeal mask airway (PLMA)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Cobra perilaryngeal airway (CobraPLA)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Laryngeal tube suction (LTS)
Number of subjects: 139
Study: 16718399

Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diet
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 30
Study: 12540117

Group type: COMPARATOR
Intervention: Hybrid resin composite (Z100)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Flowable resin composite (Filtek Flow)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Flowable resin composite (Filtek Flow) + Hybrid resin composite (Z100); light cured separately
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Flowable resin composite (Filtek Flow) + Hybrid resin composite (Z100); co-cured
Number of subjects: 20
Study: 10941879

Group type: EXPERIMENTAL
Intervention: CLA supplementation (3 g/d)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo (sunflower oil)
Number of subjects: 17
Study: 8792787

Group type: EXPERIMENTAL
Intervention: Feedback on performance
Number of subjects: 16

Group type: COMPARATOR
Intervention: Knowledge of guidelines and review criteria
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Actions taken in response to interventions
Number of subjects: 16
Study: 1464274

Group type: EXPERIMENTAL
Intervention: Slow discontinuation of antiepileptic drugs (AEDs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Routine maintenance of antiepileptic drugs (AEDs)
Number of subjects: 0
Study: 6389040

Group type: EXPERIMENTAL
Intervention: Polyadenylic‐polyuridylic acid
Number of subjects: 300

Group type: COMPARATOR
Intervention: Conventional treatment alone
Number of subjects: 300
Study: 31880760

Group type: EXPERIMENTAL
Intervention: Rhythmic transcranial magnetic stimulation
Number of subjects: 55
Study: 28641407

Group type: COMPARATOR
Intervention: Atorvastatin 20 mg/day
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Ezetimibe 10 mg/day and atorvastatin 20 mg/day
Number of subjects: 100
Study: 25621239

Group type: EXPERIMENTAL
Intervention: Intranasal splints after PIT (Group A)
Number of subjects: 100

Group type: COMPARATOR
Intervention: No intranasal splints after PIT (Group B)
Number of subjects: 100
Study: 23504926

Group type: EXPERIMENTAL
Intervention: Aerobic training (AER)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Resistance training (RES)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Both AER and RES
Number of subjects: 31
Study: 21674711

Group type: EXPERIMENTAL
Intervention: CDAI scores calculated for symptomatic recurrence
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: CDAI scores calculated for asymptomatic subjects
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: CDAI scores compared to endoscopic appearance using the Rutgeerts score
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Combination of symptom assessment plus endoscopic evidence of recurrence
Number of subjects: 93
Study: 19506137

Group type: EXPERIMENTAL
Intervention: Intralipid infusion
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Nicotinic acid
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (isotonic sodium chloride solution infusion)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Glucose infusion
Number of subjects: 10
Study: 16469978

Group type: EXPERIMENTAL
Intervention: Monounsaturated fatty acids (MUFA diet)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Saturated fatty acids (SFA diet)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: n-3 fatty acids (3.6 g n‐3 fatty acids/d)
Number of subjects: 162
Study: 14769089

Group type: COMPARATOR
Intervention: Subliminal evaluative conditioning (pairing the word 'I' with positive trait terms)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Subliminal evaluative conditioning
Number of subjects: 5
Study: 11685167

Group type: EXPERIMENTAL
Intervention: Amiodarone (1 g/d intravenously for 48 hours, then 400 mg/d orally until discharge)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Propranolol (1 mg intravenously every 6 hours for 48 hours, then 20 mg orally four times a day until discharge)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 102

Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 102
Study: 9799348

Group type: EXPERIMENTAL
Intervention: Pethidine (100 mg by intramuscular injection)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Diclofenac (75 mg by intramuscular injection)
Number of subjects: 12
Study: 8306277

Group type: EXPERIMENTAL
Intervention: Immunoscintigraphy
Number of subjects: 0
Study: 3180632

Group type: EXPERIMENTAL
Intervention: Bumetanide (3 mg oral and intravenous doses)
Number of subjects: 10
Study: 30287523

Group type: EXPERIMENTAL
Intervention: Duvelisib 25 mg orally twice daily
Number of subjects: 319

Group type: COMPARATOR
Intervention: Ofatumumab IV
Number of subjects: 319
Study: 27813670

Group type: EXPERIMENTAL
Intervention: Shared Decision Making (SDM) intervention
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (matched patients without SDM)
Number of subjects: 200
Study: 26107742

Group type: EXPERIMENTAL
Intervention: Synchronized nasal intermittent mandatory ventilation (S-NIMV)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Nonsynchronized nasal intermittent mandatory ventilation (NIMV)
Number of subjects: 14
Study: 23954210

Group type: EXPERIMENTAL
Intervention: Immediate office‐based probing within two weeks (n = 31)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Observation and deferred facility probing (n = 26)
Number of subjects: 57
Study: 21123460

Group type: EXPERIMENTAL
Intervention: Mediterranean diet (MedDiet) enriched in monounsaturated fatty acids
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Mediterranean diet (MedDiet)
Number of subjects: 20
Study: 18573697

Group type: EXPERIMENTAL
Intervention: SNaPshot technique for fetal genotyping of paternal mutation in maternal blood
Number of subjects: 3
Study: 16781967

Group type: EXPERIMENTAL
Intervention: Web-based physical activity intervention
Number of subjects: 319

Group type: COMPARATOR
Intervention: Print-based physical activity intervention
Number of subjects: 319
Study: 14727476

Group type: EXPERIMENTAL
Intervention: Diclofenac patch
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0